Health insurance has long been typecast as the industry that says “no,” mails confusing letters, and cleans up the administrative mess after care happens. Even inside payer organizations, we’ve historically

In the pharmaceutical world, AI drug discovery is a topic that has been discussed endlessly with everyone, zeroing in on the belief that algorithms can magically trim timelines and drastically

When Evommune went public late last year, it said data from a proof-of-concept test of one of its atopic dermatitis drug candidates would come in the first half of 2026.

The problem is that what you can’t see can still pose a significant risk to patient safety. Adenosine triphosphate (ATP) is found in all living cells, from bacteria to blood

The next frontier for cell therapy is shaping up to be in vivo treatments for autoimmune disease, and Eli Lilly is getting a contender through the acquisition of startup Orna

NYU Langone Health is launching a new telehealth model for Alzheimer’s and memory care through a partnership with Isaac Health, a virtual platform for specialist-led dementia care. Founded in 2022,

Rashes and lesions caused by cutaneous sarcoidosis can cover much of the body, sometimes becoming disfiguring. There are no FDA-approved treatments for this rare disease, which has been overlooked by

For years, Congress has signaled that it wants to crack down on Pharmacy Benefit Managers, the middle men that have come under fire for their vertical integration with insurers and

OpenEvidence has raised nearly $700 million since it was founded in 2021. Last month, the Miami-based company closed a $250 million Series funding round that brought its valuation to a

There is a sense that the AI in healthcare landscape is shifting as Anthropric and OpenAI vie for industry dominance. Both have sought to build up their healthcare offerings over